EE200000319A - hGRF-PEG konjugaatide saitspetsiifiline valmistamismeetod, hGRF-PEG konjugaadid, nende vaheühendid, kasutamine ja farmatseutiline kompositsioon - Google Patents

hGRF-PEG konjugaatide saitspetsiifiline valmistamismeetod, hGRF-PEG konjugaadid, nende vaheühendid, kasutamine ja farmatseutiline kompositsioon

Info

Publication number
EE200000319A
EE200000319A EEP200000319A EEP200000319A EE200000319A EE 200000319 A EE200000319 A EE 200000319A EE P200000319 A EEP200000319 A EE P200000319A EE P200000319 A EEP200000319 A EE P200000319A EE 200000319 A EE200000319 A EE 200000319A
Authority
EE
Estonia
Prior art keywords
hgrf
peg conjugates
intermediates
site
preparation
Prior art date
Application number
EEP200000319A
Other languages
English (en)
Estonian (et)
Inventor
Maria Veronese Francesco
Caliceti Paolo
Schiavon Oddone
Original Assignee
Applied Research Systems Ars Holding N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems Ars Holding N.V. filed Critical Applied Research Systems Ars Holding N.V.
Publication of EE200000319A publication Critical patent/EE200000319A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Birds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EEP200000319A 1997-12-03 1998-12-01 hGRF-PEG konjugaatide saitspetsiifiline valmistamismeetod, hGRF-PEG konjugaadid, nende vaheühendid, kasutamine ja farmatseutiline kompositsioon EE200000319A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97121264A EP0922446A1 (de) 1997-12-03 1997-12-03 Lösungsphase Verfahrung zur ortspezifischer Herstellung von GRF-PEG Konjugaten
PCT/EP1998/007748 WO1999027897A1 (en) 1997-12-03 1998-12-01 Site-specific preparation of polyethylene glycol-grf conjugates

Publications (1)

Publication Number Publication Date
EE200000319A true EE200000319A (et) 2001-08-15

Family

ID=8227732

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000319A EE200000319A (et) 1997-12-03 1998-12-01 hGRF-PEG konjugaatide saitspetsiifiline valmistamismeetod, hGRF-PEG konjugaadid, nende vaheühendid, kasutamine ja farmatseutiline kompositsioon

Country Status (29)

Country Link
US (3) US6528485B1 (de)
EP (2) EP0922446A1 (de)
JP (2) JP2001524505A (de)
KR (1) KR100561768B1 (de)
CN (1) CN1149967C (de)
AR (1) AR017780A1 (de)
AT (1) ATE236607T1 (de)
AU (1) AU755285B2 (de)
BG (1) BG64815B1 (de)
BR (1) BR9815159A (de)
CA (1) CA2312004C (de)
DE (1) DE69813291T2 (de)
DK (1) DK1037587T3 (de)
EA (1) EA004269B1 (de)
EE (1) EE200000319A (de)
ES (1) ES2194376T3 (de)
HU (1) HUP0100507A3 (de)
IL (2) IL136551A0 (de)
NO (1) NO327238B1 (de)
NZ (1) NZ504570A (de)
PL (1) PL192082B1 (de)
PT (1) PT1037587E (de)
SI (1) SI1037587T1 (de)
SK (1) SK8242000A3 (de)
TR (1) TR200001615T2 (de)
TW (1) TWI254641B (de)
UA (1) UA73716C2 (de)
WO (1) WO1999027897A1 (de)
ZA (1) ZA9811068B (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010055581A1 (en) 1994-03-18 2001-12-27 Lawrence Tamarkin Composition and method for delivery of biologically-active factors
US6407218B1 (en) * 1997-11-10 2002-06-18 Cytimmune Sciences, Inc. Method and compositions for enhancing immune response and for the production of in vitro mabs
US7229841B2 (en) * 2001-04-30 2007-06-12 Cytimmune Sciences, Inc. Colloidal metal compositions and methods
US7256258B2 (en) 2000-10-05 2007-08-14 Ares Trading S.A. Regioselective liquid phase pegylation
EP1234583A1 (de) 2001-02-23 2002-08-28 F. Hoffmann-La Roche Ag PEG-Konjugate des HGF-NK4
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
WO2003062290A1 (en) * 2002-01-16 2003-07-31 Biocompatibles Uk Limited Polymer conjugates
US7998705B2 (en) * 2002-08-06 2011-08-16 FUJIFILM Diosynth Biotechnologies U.S.A., Inc Increased dynamic binding capacity in ion exchange chromatography by addition of polyethylene glycol
US20060128615A1 (en) * 2002-09-18 2006-06-15 Pierrette Gaudreau Ghrh analogues
GB0301014D0 (en) * 2003-01-16 2003-02-19 Biocompatibles Ltd Conjugation reactions
US7662915B2 (en) * 2003-01-18 2010-02-16 Pegsphere Co., Ltd. Peptides having protected amines of untargeted sites, methods for production thereof and of specifically conjugated PEG peptides using the same
WO2005010163A2 (en) * 2003-07-15 2005-02-03 Barros Research Institute Compositions and methods for immunotherapy of human immunotherapy of human immunodeficiency virus (hiv)
WO2005010040A1 (en) * 2003-07-15 2005-02-03 Barros Research Institute Eimeria tenella antigen for immunotherapy of coccidiosis
JP2008504216A (ja) * 2003-12-02 2008-02-14 サイトイミューン サイエンシズ インコーポレイテッド モノクローナル抗体の生成のための方法および組成物
JP4833862B2 (ja) * 2004-01-28 2011-12-07 サイトイミューン サイエンシズ インコーポレイテッド 官能化コロイド金属組成物および方法
CN100355784C (zh) * 2004-02-12 2007-12-19 江苏恒瑞医药股份有限公司 聚乙二醇修饰α－干扰素1b的制备方法
US20050261475A1 (en) * 2004-02-13 2005-11-24 Harvard Medical School Solid-phase capture-release-tag methods for phosphoproteomic analyses
US6986264B1 (en) * 2004-07-15 2006-01-17 Carrier Corporation Economized dehumidification system
MX350293B (es) 2004-11-12 2017-09-04 Bayer Healthcare Llc Modificacion dirigida al sitio del factor viii.
BRPI0614185B1 (pt) * 2005-07-26 2015-10-27 Rhodia polímero com grupos substituintes poli (alquileneoxi) pendentes, composição de cuidados pessoais e método para cuidar do cabelo ou da pele
US20070238656A1 (en) * 2006-04-10 2007-10-11 Eastman Kodak Company Functionalized poly(ethylene glycol)
EP2444499A3 (de) 2006-05-02 2012-05-09 Allozyne, Inc. Aminosäuresubstituierte Moleküle
US20080096819A1 (en) * 2006-05-02 2008-04-24 Allozyne, Inc. Amino acid substituted molecules
PL2054074T3 (pl) * 2006-08-04 2015-03-31 Prolong Pharmaceuticals Llc Zmodyfikowana erytropoetyna
US20080083154A1 (en) * 2006-10-05 2008-04-10 Timothy M Gregory Bait retention fish hook
RU2345608C2 (ru) * 2007-01-09 2009-02-10 Государственное образовательное учреждение высшего профессионального образования "Северо-Кавказский государственный технический университет" Вареная колбаса с использованием pse свинины и способ ее производства
CA2707840A1 (en) 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
CA2700378A1 (en) * 2007-09-21 2009-03-29 Cytimmune Sciences, Inc. Nanotherapeutic colloidal metal compositions and methods
US20110014118A1 (en) * 2007-09-21 2011-01-20 Lawrence Tamarkin Nanotherapeutic colloidal metal compositions and methods
WO2009062151A1 (en) 2007-11-08 2009-05-14 Cytimmune Sciences, Inc. Compositions and methods for generating antibodies
EP2362881B1 (de) * 2008-11-04 2019-03-13 Janssen Pharmaceutica NV Crhr2-peptid-agonisten und anwendungen davon
AU2010225523B2 (en) * 2009-03-20 2012-05-24 Hanmi Science Co., Ltd. Method for preparing a site-specific physiologically active polypeptide conjugate
EP2421548A4 (de) * 2009-04-20 2012-09-26 Theratechnologies Inc Verwendung von (hexenoyl-trans-3)hgrf(l-44)nh2 und simvastatin in einer kombinationstherapie
WO2010121351A1 (en) * 2009-04-20 2010-10-28 Theratechnologies Inc. Use of (hexenoyl trans-3)hgrf(1-44)nh2 and ritonavir in combination therapy
EP2445536B1 (de) 2009-06-22 2016-06-08 Burnham Institute for Medical Research Verfahren und zusammensetzungen mit peptiden und proteinen mit c-terminalen elementen
CN102711801A (zh) 2009-11-04 2012-10-03 詹森药业有限公司 用顶压素样肽治疗心力衰竭的方法
WO2012118778A1 (en) 2011-02-28 2012-09-07 Sanford-Burnham Medical Research Institute Truncated car peptides and methods and compositions using truncated car peptides
KR20140027284A (ko) 2011-04-21 2014-03-06 쎄러테크놀로지스 인코포레이티드 성장 호르몬 방출 인자(grf) 유사체 및 이의 용도
WO2012166585A2 (en) 2011-05-31 2012-12-06 Airware, Inc. Re-calibration of ab ndir gas sensors
US10179801B2 (en) 2011-08-26 2019-01-15 Sanford-Burnham Medical Research Institute Truncated LYP-1 peptides and methods and compositions using truncated LYP-1 peptides
WO2013190520A2 (en) 2012-06-22 2013-12-27 The General Hospital Corporation Gh-releasing agents in the treatment of vascular stenosis and associated conditions
US10064940B2 (en) 2013-12-11 2018-09-04 Siva Therapeutics Inc. Multifunctional radiation delivery apparatus and method
CA2986927C (en) 2015-05-28 2023-12-19 Institut National De La Recherche Scientifique Inhibitors of prototypic galectin dimerization and uses thereof
DK3445778T3 (da) * 2016-04-19 2020-10-12 Griffon Pharmaceuticals Int Sa Pegylerede bioaktive peptider og anvendelser deraf
CN110317826B (zh) * 2019-05-22 2020-11-10 中国农业大学 调控PvGRF9含量或活性的物质在调控植物茎生长发育中的应用
EP4076499B1 (de) 2019-12-19 2025-07-16 Transfert Plus Societe en Commandite Verwendung von aus glialzellen abgeleiteten neurotrophen faktoren (gdnf) für die behandlung von enterischen neuropathien
WO2021133407A1 (en) 2019-12-27 2021-07-01 Compagnie Generale Des Etablissements Michelin Rubber mix with high specific surface area and high structure acetylene carbon black
WO2022165039A1 (en) 2021-01-28 2022-08-04 Talem Therapeutics Llc Anti-sars-cov-2 spike glycoprotein antibodies and the therapeutic use thereof
EP4601691A1 (de) 2022-10-14 2025-08-20 Talem Therapeutics LLC Anti-trkb/cd3-antikörper und verwendungen davon

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4563352A (en) * 1982-10-04 1986-01-07 The Salk Institute For Biological Studies Human pancreatic GRF
EP0400472B1 (de) * 1989-05-27 1996-04-03 Sumitomo Pharmaceuticals Company, Limited Verfahren für die Herstellung von Polyethylenglykolderivate und modifizierte Proteine.
NZ238748A (en) * 1990-06-29 1993-09-27 Hoffmann La Roche Growth hormone releasing factor (grf) analogues
JP3051145B2 (ja) * 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
JPH05507939A (ja) * 1991-04-09 1993-11-11 エフ・ホフマン―ラ　ロシユ　アーゲー 成長ホルモン放出因子の類似体
EP0518295A3 (en) * 1991-06-14 1993-09-01 Millipore Corporation Allyl side chain protection in peptide synthesis
FR2687681B1 (fr) * 1992-02-20 1995-10-13 Transgene Sa Conjugues polyethyleneglycol-hirudine, leur procede de preparation et leur emploi pour le traitement des thromboses.
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
AU7273196A (en) * 1995-11-03 1997-05-29 Theratechnologies Inc. Method of grf peptides synthesis

Also Published As

Publication number Publication date
WO1999027897A9 (en) 1999-09-30
EP1037587A1 (de) 2000-09-27
EA004269B1 (ru) 2004-02-26
AU1563399A (en) 1999-06-16
AR017780A1 (es) 2001-10-24
DE69813291T2 (de) 2003-11-13
US7317002B2 (en) 2008-01-08
EP1037587B1 (de) 2003-04-09
US6869932B2 (en) 2005-03-22
JP5431874B2 (ja) 2014-03-05
CN1149967C (zh) 2004-05-19
HUP0100507A2 (hu) 2001-08-28
ES2194376T3 (es) 2003-11-16
TWI254641B (en) 2006-05-11
ZA9811068B (en) 1999-06-28
BR9815159A (pt) 2000-10-10
SI1037587T1 (en) 2003-08-31
JP2001524505A (ja) 2001-12-04
KR20010032494A (ko) 2001-04-25
EA200000601A1 (ru) 2000-12-25
NO327238B1 (no) 2009-05-18
EP0922446A1 (de) 1999-06-16
PL192082B1 (pl) 2006-08-31
HK1034203A1 (en) 2001-10-19
NZ504570A (en) 2003-10-31
BG64815B1 (bg) 2006-05-31
HUP0100507A3 (en) 2001-11-28
IL136551A (en) 2008-12-29
TR200001615T2 (tr) 2000-12-21
AU755285B2 (en) 2002-12-05
CN1280483A (zh) 2001-01-17
ATE236607T1 (de) 2003-04-15
DK1037587T3 (da) 2003-07-28
US20050159353A1 (en) 2005-07-21
PL341139A1 (en) 2001-03-26
CA2312004A1 (en) 1999-06-10
NO20002664D0 (no) 2000-05-24
WO1999027897A1 (en) 1999-06-10
BG104484A (bg) 2000-12-29
JP2010024245A (ja) 2010-02-04
UA73716C2 (en) 2005-09-15
CA2312004C (en) 2009-05-19
IL136551A0 (en) 2001-06-14
US6528485B1 (en) 2003-03-04
DE69813291D1 (de) 2003-05-15
PT1037587E (pt) 2003-08-29
SK8242000A3 (en) 2001-01-18
NO20002664L (no) 2000-07-13
US20040029794A1 (en) 2004-02-12
KR100561768B1 (ko) 2006-03-16

Similar Documents

Publication Publication Date Title
EE200000319A (et) hGRF-PEG konjugaatide saitspetsiifiline valmistamismeetod, hGRF-PEG konjugaadid, nende vaheühendid, kasutamine ja farmatseutiline kompositsioon
EE9500064A (et) Asendatud 1H-imidasoolid, nende valmistamismeetodid ja farmatseutilised kompositsioonid
EE03263B1 (et) Erütromütsiini derivaadid, nende valmistamismeetod, farmatseutiline kompositsioon ja vaheühendid
EE9900018A (et) Asendatud püridiinid, nende kasutamine ja farmatseutilised kompositsioonid
HUP0102307A3 (en) Bispidine derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates
FI973733L (fi) Farmaseuttinen valmiste ja menetelmä sen valmistamiseksi
SK284171B9 (sk) Derivát 4''-substituovaného-9-deoxo-9a-aza-9a-homoerytromycínu A, spôsob a medziprodukty na jeho prípravu, jeho použitie a farmaceutická kompozícia s jeho obsahom
ID22891A (id) Komposisi farmasi untuk kombinasi piperidinoalkanol-dekongestan
EE200000225A (et) Arüüloksüalküüldialküülamiinid, nende valmistamismeetodid ja farmatseutiline kompositsioon
EE9800302A (et) Arüülglütsiinamiidi derivaadid, nende valmistamismeetod ja kasutamine ning farmatseutiline preparaat
BR9603429A (pt) Derivado de 11-(fenila substituída) estra-4,9-dieno processo de preparação do mesmo composição farmacêutica e uso deste derivado
FI953898A7 (fi) Glysiiniamidijohdannaisia, menetelmiä niiden valmistamiseksi ja niitä sisältäviä lääkeaineita
FI952550A7 (fi) Uudet N-pyridyylikarboksamidit ja johdannaiset, menetelmät niiden valmistamiseksi ja niitä sisältävät farmaseuttiset koostumukset
EE03825B1 (et) 2-tsüanoiminoimidasooli derivaadid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid
EE04681B1 (et) 3,6-poolketaalid 9a-asaliidide klassist, nende valmistamismeetod ja farmatseutiline kompositsioon
EE9800200A (et) Bensoüülguanidiini derivaadid, nende valmistamismeetod, kasutamine ja farmatseutiline kompositsioon
EE04346B1 (et) Asoolid, nende valmistamismeetod, kasutamine ja farmatseutiline kompositsioon
EE200100173A (et) 2-fenüülpüraan-4-ooni derivaadid, nende valmistamismeetod ja kasutamine, vaheühendite kasutamine jafarmatseutiline kompositsioon
EE03996B1 (et) Farmatseutilised kompositsioonid, nende valmistamismeetod ja kasutamine
FI972988L (fi) Menetelmiä ja farmaseuttisia koostumuksia, joissa käytetään desmetyyliselegiliiniä
EE04398B1 (et) Asendatud 1,2,3,4,5,6-heksahüdro-2,6-metano-3-bensasotsiin-10-oolid, nende valmistamise meetod ja kasutamine ravimitena
FI960316L (fi) Oksatiolaanit, menetelmä niiden valmistamiseksi ja niitä sisältävät farmaseuttiset koostumukset
EE03387B1 (et) Kombineeritud ravimpreparaat, selle kasutamine ja meetod selle valmistamiseks
NZ291597A (en) Carboxycyclopropan-1-yl derivatives, preparation, pharmaceutical compositions and intermediates thereof
HUP0000203A3 (en) Naphthyl derivatives, pharmaceutical compositions containing them and intermediates

Legal Events

Date Code Title Description
GB1A Change in the ownership or in the address of the owner